Upregulation of CDK4/6—RB pathway is common in breast cancer, especially in luminal subtypes, where cyclin D1 amplification is identified in 58% of luminal B and 29% of luminal A cancers and CDK4 amplification in 25% and 14%, respectively [85]. Here, CDK4 is linked to breast carcinoma.